Comparison 2. n‐3 LCPUFA supplementation versus placebo or no supplementation ‐ specific forms of allergy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Food allergies (with sensitisation): medically diagnosed IgE mediated	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Up to 12 months	1	117	Risk Ratio (M‐H, Random, 95% CI)	0.13 [0.02, 0.95]
1.2 12 to 36 months	2	825	Risk Ratio (M‐H, Random, 95% CI)	0.58 [0.18, 1.88]
1.3 Beyond 36 months	1	706	Risk Ratio (M‐H, Random, 95% CI)	1.43 [0.63, 3.26]
2 Food allergies (+/‐ sensitisation): medically diagnosed/parental reported	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Up to 12 months	1	117	Risk Ratio (M‐H, Fixed, 95% CI)	0.13 [0.02, 0.95]
2.2 12 to 36 months	4	973	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.40, 1.30]
2.3 Beyond 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	1.43 [0.63, 3.26]
3 Atopic dermatitis/Eczema (with sensitisation): medically diagnosed IgE mediated	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 Up to 12 months	1	117	Risk Ratio (M‐H, Fixed, 95% CI)	0.38 [0.13, 1.11]
3.2 12 to 36 months	2	823	Risk Ratio (M‐H, Fixed, 95% CI)	0.61 [0.39, 0.95]
3.3 Beyond 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	0.84 [0.57, 1.23]
4 Atopic dermatitis/Eczema (+/‐ sensitisation): medically diagnosed/parental reported	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 Up to 12 months	2	203	Risk Ratio (M‐H, Random, 95% CI)	0.76 [0.22, 2.62]
4.2 12 to 36 months	4	973	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.69, 1.33]
4.3 Beyond 36 months	2	1237	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.68, 1.13]
5 Allergic rhinitis/Hay fever (with sensitisation): medically diagnosed IgE mediated	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Up to 12 months	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 12 to 36 months	2	825	Risk Ratio (M‐H, Fixed, 95% CI)	0.47 [0.07, 3.06]
5.3 Beyond 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.44, 1.54]
6 Allergic rhinitis/Hay fever (+/‐ sensitisation): medically diagnosed/parental reported	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 Up to 12 months	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 12 to 36 months	2	805	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.25, 1.12]
6.3 Beyond 36 months	2	1169	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.81, 1.30]
7 Asthma/Wheeze (with sensitisation): medically diagnosed IgE mediated	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
7.1 Up to 12 months	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.2 12 to 36 months	2	824	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.21, 3.49]
7.3 Beyond 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.34, 3.58]
8 Asthma/Wheeze (+/‐ sensitisation): medically diagnosed/parental reported	7		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
8.1 Up to 12 months	1	83	Risk Ratio (M‐H, Fixed, 95% CI)	1.26 [0.54, 2.94]
8.2 12 to 36 months	4	955	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.73, 1.18]
8.3 Beyond 36 months	3	1697	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.78, 1.13]